Michael Drobbin, DO
Otolaryngology · Danbury, CTNPI 1881981371
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,204 of the $3,371 with a category attached, or 65.4%. Stryker accounts for 71.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $1,695 and has fallen 77.4% since, to $383 in 2022.
Across 43 payments — averaging $78.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Sanofi$248
- Intersect ENT, Inc.$202
- Acclarent, Inc$122
- AbbVie$113
- Sanofi-aventis U.S. LLC$99
- plus $175 from 8 others
What the payments were for
- Travel & lodging$2,20465%
- Food & beverage$1,06832%
- Education$993%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 15 | $2,412 |
| Sanofi | 7 | $248 |
| Intersect ENT, Inc. | 4 | $202 |
| Acclarent, Inc | 1 | $122 |
| AbbVie | 5 | $113 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| GSK | 3 | $49 |
| Optinose US, Inc. | 1 | $23 |
| Pfizer | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Aerin Medical Inc. | 1 | $18 |
| Merck | 1 | $15 |
| Alk-abello, Inc | 1 | $15 |
| Glenmark Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,371 in reported general payments places this provider in the 70th percentile of 119 otolaryngology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 244 | $2,458 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 22 | $2,352 |
| Azelastine Hcl | 101 | $1,519 |
| Fluocinolone Acetonide Oil | 27 | $1,058 |
| Ofloxacin | 30 | $801 |
| Omeprazole | 56 | $636 |
| Ipratropium Bromide | 29 | $603 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $278 |
| Methylprednisolone | 34 | $247 |
| Mupirocin | 29 | $222 |
| Famotidine | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Danbury
- Dov BlochDanbury$7K
- Jay KlarsfeldDanbury$4K
- Danielle WarnerDanbury$3K
- Mark DelacureDanbury$2K
- Michael BardDanbury$2K
- Sara PaiNew Haven$160K
- Richard ManesNew Haven$67K
- Howard StupakWestport$48K
- Belachew TessemaFarmington$45K
- Seth BrownFarmington$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.